US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioStem Technologies, Inc.

4.87

+0.16253.45%

Volume:58.19K

Turnover:280.78K

Market Cap:81.66M

PE:4.28

High:4.90

Open:4.75

Low:4.70

Close:4.71

52wk High:28.26

52wk Low:4.07

Shares:16.77M

Float Shares:16.34M

Volume Ratio:0.93

T/O Rate:0.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.14

EPS(LYR):1.95

ROE:79.34%

ROA:14.24%

PB:1.70

PE(LYR):2.50

Loading ...

Overview Company News Filings

Biostem Technologies Expands Partnership With the Florida Panthers as a Sponsor for the 13TH Season of the “Heroes Among US” Program

THOMSON REUTERS

Biostem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer

THOMSON REUTERS

Biostem Technologies, Inc. Q2 EPS USD -0.03

THOMSON REUTERS

Biostem Technologies Appoints Brandon Poe as Chief Financial Officer

THOMSON REUTERS

BRIEF-Biostem Technologies Completes Enrollment In Clinical Trial Evaluating Bioretain® Amnion Chorion For Treatment Of Diabetic Foot Ulcers

Press Release: Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year(R) 2025 Florida Award finalist

Press Release: BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BSEM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSEM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","market":"US","secType":"STK","nameCN":"BioStem Technologies, Inc.","latestPrice":4.87,"timestamp":1760731200000,"preClose":4.7075,"halted":0,"volume":58194,"delay":15,"floatShares":16338436,"shares":16767777,"eps":1.13827,"marketStatus":"Post-Mkt","change":0.1625,"latestTime":"10-17 16:00:00 EDT Delay","open":4.75,"high":4.9,"low":4.7,"amount":280778.9654999998,"amplitude":0.042485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.13827,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1760745600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":4.7075,"volumeRatio":0.928581},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","floatShares":16338436,"roa":"14.24%","roe":"79.34%","lyrEps":1.947915,"volumeRatio":0.928581,"shares":16767777,"dividePrice":0,"high":4.9,"amplitude":0.042485,"preClose":4.7075,"low":4.7,"week52Low":4.065,"pbRate":"1.70","psRate":"0.27","week52High":28.2565,"institutionHeld":0,"latestPrice":4.87,"eps":1.13827,"divideRate":0,"volume":58194,"delay":15,"ttmEps":1.13827,"open":4.75,"prevYearClose":13.84,"prevWeekClose":4.307,"prevMonthClose":4.69,"prevQuarterClose":4.69,"fiveDayClose":4.307,"twentyDayClose":5.16,"sixtyDayClose":11.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSEM\",params:#limit:5,,,undefined,":[{"date":"2025-08-14","symbol":"BSEM","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755158400000,"name":null,"time":"","dateTimestamp":1755144000000,"actualEps":null},{"date":"2025-05-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747080000000,"name":null,"time":"Post Market","dateTimestamp":1747022400000,"actualEps":null},{"date":"2025-04-14","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1744660800000,"name":null,"time":"Post Market","dateTimestamp":1744603200000,"actualEps":null},{"date":"2024-11-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1731445200000,"name":null,"time":"Post Market","dateTimestamp":1731387600000,"actualEps":null},{"date":"2024-08-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723492800000,"name":null,"time":"Post Market","dateTimestamp":1723435200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSEM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BSEM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSEM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2572546750","title":"Biostem Technologies Expands Partnership With the Florida Panthers as a Sponsor for the 13TH Season of the “Heroes Among US” Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2572546750","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572546750?lang=en_us&edition=fundamental","pubTime":"2025-10-03 00:00","pubTimestamp":1759420800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nTUA9VY8FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BSEM","BK4007"],"gpt_icon":0},{"id":"2561461578","title":"Biostem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2561461578","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561461578?lang=en_us&edition=fundamental","pubTime":"2025-08-21 19:00","pubTimestamp":1755774001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nTUA44FGFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BSEM"],"gpt_icon":0},{"id":"2559096192","title":"Biostem Technologies, Inc. Q2 EPS USD -0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2559096192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559096192?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:06","pubTimestamp":1755201960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX100977:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BSEM"],"gpt_icon":0},{"id":"2559961569","title":"Biostem Technologies Appoints Brandon Poe as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2559961569","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559961569?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201704,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA1S5NLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BSEM","BK4534","BK4588","BK4548","BK4585","BK4007","BK4121","ILMN"],"gpt_icon":0},{"id":"2545411218","title":"BRIEF-Biostem Technologies Completes Enrollment In Clinical Trial Evaluating Bioretain® Amnion Chorion For Treatment Of Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2545411218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545411218?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:26","pubTimestamp":1750681600,"startTime":"0","endTime":"0","summary":"BRIEF-Biostem Technologies Completes Enrollment In Clinical Trial Evaluating Bioretain Amnion Chorion For Treatment Of Diabetic Foot UlcersJune 23 (Reuters) - Biostem Technologies Inc BSEM.PK:BIOSTEM ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA34H69B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BSEM"],"gpt_icon":0},{"id":"2537948990","title":"Press Release: Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year(R) 2025 Florida Award finalist","url":"https://stock-news.laohu8.com/highlight/detail?id=2537948990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537948990?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:04","pubTimestamp":1747911840,"startTime":"0","endTime":"0","summary":"POMPANO BEACH, Fla., May 22, 2025  -- BioStem Technologies, Inc.  , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP  finalist for the prestigious Entrepreneur Of The Year 2025 Florida Award.An independent panel of judges selected Jason Matuszewski, CEO of BioStem Technologies, as one of 25 finalists, recognizing his entrepreneurial spirit, purpose, growth, and lasting impact in creating long-term value.Jason Matuszewski, CEO of BioStem Technologies, commented: \"Being named a finalist for this award is a tremendous honor and a reflection of the incredible work our team performs every day as leaders in the advanced wound care sector. It's humbling to see the impact BioStem and our products have made, not only in improving the lives of patients with chronic wounds nationwide, but also in contributing to the health and ec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4585","BK4588","TM","BSEM","BK4007","BK4232","BK4022","BK4555","03160","R","BK4604"],"gpt_icon":0},{"id":"2535978251","title":"Press Release: BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535978251","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535978251?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:45","pubTimestamp":1747082700,"startTime":"0","endTime":"0","summary":"-- Preliminary net revenue increased 73% to $72.5 million for Q1 2025,-- Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share. -- Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million. In Q1 2025, BioStem announced key milestones that further solidify its leadership in placental-derived products for wound care. The Company has received Institutional Review Board  approval to initiate a new clinical trial evaluating BioREtain Amnion Chorion  for the treatment of venous leg ulcers . This study is BioStem's third prospective clinical trial and reflects its ongoing commitment to building a rob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSEM"],"gpt_icon":0},{"id":"2527714952","title":"Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527714952","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527714952?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:18","pubTimestamp":1744661880,"startTime":"0","endTime":"0","summary":"BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million. Million, contributing to a total of $301.8 Million in revenue for 2024. -- Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share,-- Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million. Mr. Matuszewski continued: \"BioStem remains committed to demonstrating the clinical effectiveness of our BioREtain technology. Since the fourth quarter, we have initiated three clinical trials evaluating the efficacy of BioREtain-powered products against the standard of care in patients with diabetic foot ulcers or venous leg ulcers. Separately, we were pleased to announce groundbreaking results in the fourth quarter from a retrospective study on DFU wound closure, which was published in the peer-reviewed International Wound Journal. These trials are aimed at demonstrating clinical superiority for healthcare professionals and payers, w","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSEM"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}